Fosun Pharma to joint-venture focused on the maternal and infant industry
date：2018-06-07
browse：（1069）
Keyword： Fosun Pharma focused on the maternal and infant industry
On May 14, Fosun Pharma (600196) announced that the company and its holding subsidiary, Jiangsu Wanbang Cloud Health Technology Co., Ltd. (hereinafter referred to as “Wanbang Cloud Health”) signed a “JV Contract” with its related parties Fosun Health Holdings and Haitun International said parties will invest and establish Shanghai Xingbao Zhikang Technology Co., Ltd. (temporary name to later be finalized by the registration authority, hereinafter referred to as “Xingbao Zhikang”). The transaction constitutes affiliated transaction. The registered capital of Xingbao Zhikang is RMB 18 million.
The latest article
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
